0001610717-24-000433.txt : 20240822
0001610717-24-000433.hdr.sgml : 20240822
20240822175948
ACCESSION NUMBER: 0001610717-24-000433
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240820
FILED AS OF DATE: 20240822
DATE AS OF CHANGE: 20240822
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ogden Christopher
CENTRAL INDEX KEY: 0001914523
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 241233032
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD., SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 273521219
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2024-08-20
0001501989
CytomX Therapeutics, Inc.
CTMX
0001914523
Ogden Christopher
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO
CA
94080
true
Chief Financial Officer
false
Common Stock
2024-08-20
4
M
0
6875
0
A
110061
D
Common Stock
2024-08-20
4
S
0
1984
1.2291
D
108077
D
Performance Stock Units (PSUs)
2024-08-20
4
M
0
6875
0
D
Common Stock
6875
0
D
Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
Includes 77,810 restricted stock units.
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
2024-08-22